Search
Neurogene Inc
NGNEAdd to Watchlist
31.250USD
+0.320+1.03%
Close 09-24 16:00（ET）
616.88MMarket Cap
LossP/E TTM
About Neurogene Inc Company
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Neurogene Inc Profile
Ticker SymbolNGNE
Company nameNeurogene Inc
IPO dateMar 07, 2014
CEOMcMinn (Rachel L)
Number of employees107
Security typeOrdinary Share
Fiscal year-endMar 07
Address535 W 24Th Street
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10011
Phone18772375020
Websitehttps://www.neurogene.com/
Ticker SymbolNGNE
IPO dateMar 07, 2014
CEOMcMinn (Rachel L)
Company Executives of Neurogene Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
10.11K
-67.26%
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
10.11K
-67.26%
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
10.11K
-67.26%
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
1.97K
-106.49%
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
1.97K
-106.49%
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
1.97K
-106.49%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Dr. Rachel L. Mcminn, Ph.D.
Dr. Rachel L. Mcminn, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Christine Mikail, J.D.
Ms. Christine Mikail, J.D.
President, Chief Financial Officer, Director
President, Chief Financial Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
10.11K
-67.26%
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
10.11K
-67.26%
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
10.11K
-67.26%
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
1.97K
-106.49%
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
1.97K
-106.49%
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
1.97K
-106.49%
FAQs
Who are the top five shareholders of Neurogene Inc?
The top five shareholders of Neurogene Inc are: Dr. Stuart Cobb, Ph.D.
How many institutions hold shares of Neurogene Inc (NGNE)?
As of 2026Q1, 225 institutions hold shares of Neurogene Inc, with a combined market value of approximately 17.70M, accounting for 113.37% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1041455.00.